Oxford BioDynamics Announces US Launch Of Its Checkpoint Inhibitor Response Test (EpiSwitch CiRT) For Oncology

• First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)

• Provides guidance to support critical treatment decisions on beginning or continuing treatment with this essential class of cancer therapeutic

• A significant advancement in harmonizing the prediction of response to ICI treatment, as demanded by the FDA and oncologists

• Clinically validated blood test now available to oncologists across the US; early adopter orders from oncologists are being booked

• EpiSwitch CiRT delivers best in class performance: 93% sensitivity, 82% specificity, 85% accuracy

Oxford BioDynamics Plc , a biotechnology company developing precision medicine tests for immune health based on its EpiSwitch 3D genomics platform, has announced the successful clinical validation and US launch of its Checkpoint Inhibitor Response Test (EpiSwitch CiRT).

Latest Aithority Insights: Mobile Payment App Scams on the Rise, ComEd and Better Business Bureau Warn Utility Customers

“In terms of the healthcare economics, ICIs alone cost the US healthcare system $17B annually. The ability to stratify patients based on their likelihood of response will enable the system to better manage these costs while allowing us to deliver smarter, better care to patients.”

The first-of-its-kind clinical blood test predicts the likelihood of a cancer patient’s response to an essential, widely used class of therapeutics – Immune Checkpoint Inhibitors (ICIs) – including anti-PD-L1 and anti-PD-1 immunotherapies. The robust EpiSwitch qPCR blood test has demonstrated best-in-class performance, with high sensitivity (93%), specificity (82%), and accuracy (85%) [1] across several ICI’s from multiple pharmaceutical companies and more than 15 key oncological indications.

Every cancer patient travels a unique path from diagnosis to treatment that requires making complex decisions with their doctor. Many patients are considered for ICI immunotherapy – an alternative approach to chemotherapy or radiation – that works with a patient’s immune system to fight cancer. ICIs have been the paramount breakthrough in cancer treatment and are now used against more than 15 types of cancer [2]. However, typically less than 1 in 3 patients receiving ICIs shows any benefit; instead, many experience serious toxicity events affecting almost any organ [3] as well as facing significant financial burden to pay for these specialised biologic medicines.

Rapid expansion of the checkpoint inhibitor class (with 8 currently approved and many more in the review pipeline) has led to appeals by the FDA and leading oncologists for harmonization and coordination of the latest ICI developments [4]. Robust and universal prediction of response to ICI treatment is seen as one of the key tools for harmonization: assisting physicians in their decisions on choices of treatment, protecting patients, leading to greater efficiency in drug development, reducing costs and protecting valuable resources [4].

Browse The Complete News About Aithority: Bounteous Announces Customer Data Platform Offering With Acquia

OBD’s EpiSwitch CiRT enables doctors to make an informed decision on whether to recommend beginning or continuing treatment with an ICI. Using a routine blood test rather than an invasive biopsy, CiRT offers fast, personalized guidance. OBD has partnered with NEXT Molecular Analytics (VA, USA) to clinically validate EpiSwitch CiRT within its high complexity CLIA-certified laboratory. Delivering the CiRT as an LDT is consistent with OBD and NEXT’s aim of getting these important tests into the hands of physicians to meet demand and help patients as quickly as possible.

In the past several months OBD’s market access team has engaged significantly with the early adopter community to inform oncologists about the CiRT test, obtain voice of customer feedback and prepare for the first use of the test upon launch. The response from oncologists who have engaged with Oxford Biodynamics has been encouraging and initial orders are being booked.

Dr Jon Burrows, CEO of Oxford BioDynamics, said:
“Oxford Biodynamics Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) is a very important step forward for precision medicine. EpiSwitch® CiRT directly links clinical outcome to gene regulation and with high accuracy predicts patient response. Since one in two of us will be diagnosed with cancer in our lifetime, it is essential to develop smart testing that can rapidly predict treatment response and guide us to the most efficacious therapies and maximize benefits for patients.

“In terms of the healthcare economics, ICIs alone cost the US healthcare system $17B annually. The ability to stratify patients based on their likelihood of response will enable the system to better manage these costs while allowing us to deliver smarter, better care to patients.”

Tom Reynolds, President of NEXT Molecular Analytics said:
“We are excited to be working with Oxford BioDynamics to bring this novel and sensitive Checkpoint Inhibitor Response test to oncologists and their patients in the US market. The EpiSwitch CiRT will provide oncologists with a powerful new tool to help manage complex treatment decisions with their patients.”

EpiSwitch CiRT was built using OBD’s well-established EpiSwitch 3D genomics platform, used to discover the most important drivers that determine a patient’s response to ICIs. For each patient, CiRT captures a personal fingerprint of their complex cancer genomic and immune system interactions. The EpiSwitch platform has been leveraged by leading pharma and clinical research teams for practical patient stratification in prognostic, predictive and early diagnostic applications across immuno-oncology, autoimmune and neurodegenerative indications [5-7].

Read More About Aithority News : Keysight Technologies Announces CEO Succession

[To share your insights with us, please write to sghosh@martechseries.com]